Rashidul Haque, Dinesh Mondal, Anwarul Karim, Imarot Hossain Molla et al.
BACKGROUND: The parasitic causes of diarrhea have historically been identified by use of microscopy; however, the use of this technique does not allow one to distinguish between subspecies or genotypes of parasites. Our objective was to determine, by use of modern diagnostic methods, the proportion ...
Nusrat Homaira, Stephen P. Luby, William A. Petri, Raija Vainionpää et al.
BACKGROUND: Pneumonia is the leading cause of childhood death in Bangladesh. We conducted a longitudinal study to estimate the incidence of virus-associated pneumonia in children aged <2 years in a low-income urban community in Dhaka, Bangladesh. METHODS: We followed a cohort of children for two yea...
Rashidul Haque, Cynthia J. Snider, Yue Liu, Z. Jennie et al.
Oral vaccines for polio (OPV) and rotavirus are less effective in children in the developing world. The reasons for this are not well understood. We tested for risk factors for poor response to OPV in infants from an urban slum of Dhaka, Bangladesh. Diminished serum neutralizing response to OPV, but...
Cynthia J. Snider, Khalequ Zaman, Concepción F. Estívariz, Mohammad Yunus et al.
Background Intradermal administration of fractional inactivated poliovirus vaccine (fIPV) is a dose-sparing alternative to intramuscular full dose. We assessed the recommendation of two fIPV doses or one IPV dose for routine immunization, and a fIPV booster dose for outbreak response. Methods We con...
Amanda L. Wilkinson, Khalequ Zaman, Masuma Hoque, Concepción F. Estívariz et al.
Background Novel oral poliovirus vaccine type 2 (nOPV2) was developed by modifying the Sabin strain to increase genetic stability and reduce risk of seeding new circulating vaccine-derived poliovirus type 2 outbreaks. Bivalent oral poliovirus vaccine (bOPV; containing Sabin types 1 and 3) is the vac...
Mallick Masum Billah, K. Zaman, Concepción F. Estívariz, Cynthia J. Snider et al.
Background: Introduction of inactivated polio vaccine creates challenges in maintaining the cold chain for vaccine storage and distribution. Methods: We evaluated the cold chain in 23 health facilities and 36 outreach vaccination sessions in 8 districts and cities of Bangladesh, using purposive samp...
Daniel E Velasquez-Portocarrero, Xiaoqian Wang, Margaret M. Cortese, Cynthia J. Snider et al.
Background A head-to-head comparison of the most widely used oral rotavirus vaccines has not previously been done, particularly in a high child mortality setting. We therefore aimed to compare the immunogenicity of RotaTeq (Merck, Kenilworth, NJ, USA) and Rotarix (GlaxoSmithKline, Rixensart, Belgium...
Khalequ Zaman, Concepción F. Estívariz, Michelle Morales, Mohammad Yunus et al.
Background Monovalent type 2 oral poliovirus vaccine (mOPV2) and inactivated poliovirus vaccine (IPV) are used to respond to type 2 poliovirus outbreaks. We aimed to assess the effect of two mOPV2 doses on the type 2 immune response by varying the time interval between mOPV2 doses and IPV co-adminis...
Concepción F. Estívariz, Cynthia J. Snider, Abhijeet Anand, Lee M. Hampton et al.
Background: We assessed programmatic adaptations and infants' uptake of inactivated poliovirus vaccine (IPV) after its introduction into the routine immunization schedule in Bangladesh. Methods: Using convenience and probability sampling, we selected 23 health facilities, 36 vaccinators, and 336 car...
Khalequ Zaman, Stéphanie Kovacs, Kristin VanderEnde, Asma Binte Aziz et al.
Background: After global oral poliovirus vaccine (OPV) cessation, the Strategic Advisory Group of Experts on Immunization (SAGE) currently recommends a two-dose schedule of inactivated poliovirus vaccine (IPV) beginning ≥14-weeks of age to achieve at least 90% immune response. We aimed to compare th...
Cynthia J. Snider, Khalequ Zaman, Amanda L. Wilkinson, Asma Binte Aziz et al.
Background: To inform response strategies, we examined type 1 humoral and intestinal immunity induced by 1) one fractional inactivated poliovirus vaccine (fIPV) dose given with monovalent oral poliovirus vaccine (mOPV1), and 2) mOPV1 versus bivalent OPV (bOPV). Methods: We conducted a randomized, co...
Cynthia J. Snider, Khalequ Zaman, Concepción F. Estívariz, Asma Binte Aziz et al.
In 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) recommended introduction of at least one inactivated poliovirus vaccine (IPV) dose in essential immunization programs. We evaluated systemic humoral and intestinal mucosal immunity of a sequential IPV-bivalent oral poliovirus va...